Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle

September 30, 2025 at 16:15 PM EDT

With new label, Dectomax^®-CA1 Injectable is the first and only parasite control product with conditional approval to help control economically devastating pest Cochliomyia hominivorax (New World screwworm)

Zoetis Inc. today announced that Dectomax^®-CA1 Injectable is the first and only parasite control product to receive conditional approval from the U.S. Food and Drug Administration for the prevention and treatment of infestations caused by the larvae of Cochliomyia hominivorax (myiasis), and prevention of reinfestation for 21 days. This conditional approval applies to beef cattle, female dairy cattle less than 20 months of age, pregnant beef cows, newborn calves and bulls.

Zoetis is committed to supporting livestock producers with scientific solutions for this economically devastating pest. New World screwworm poses a continuing threat to livestock health, and the financial impacts of the disease to the U.S. agricultural economy are estimated in the billions of dollars.¹

“New World screwworm has the potential to bring unprecedented economic and animal health harm to livestock producers,” said Mike Lormore, DVM, MS, MBA, Director of Cattle and Pork Technical Services at Zoetis. “Our top priority is to support keeping animals healthy and provide timely, efficacious solutions to our customers and partners. With this conditional approval, Dectomax-CA1 Injectable can now be used as part of safe, effective control measures against New World screwworm.”

As the leading animal health company, Zoetis has long supported a One Health approach to emerging and transboundary infectious diseases and has a strong track record of quickly developing innovative solutions to provide customers with the right mix of tools for their prevention and treatment strategies.

Livestock producers are encouraged to work closely with their herd veterinarian to implement strategic prevention and control measures.

Early detection of New World screwworm and rapid response are critical to protecting the health of animals and the livestock industry. Producers are encouraged to immediately report any suspicious wounds, maggots, or infestations to their local accredited veterinarian, state animal health official, or the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service. USDA APHIS animal health contacts can be found at https://www.aphis.usda.gov/contact/animal-health.

In the first half of 2026, producers and veterinarians will begin to see the 250-milliliter and 500-milliliter bottles of Dectomax^® Injectable with a new label for Dectomax^®-CA1 (doramectin injection). Dectomax-CA1 is the same effective doramectin formulation as Dectomax Injectable.

For more information on New World screwworm and the conditional approval for Dectomax-CA1 Injectable, visit zoetisus.com/NewWorldscrewworm.

Dectomax-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under NADA 141-616.

Dectomax and Dectomax-CA1 Injectable for use in cattle have a 35-day pre-slaughter withdrawal period. Do not use in female dairy cattle 20 months of age or older. Do not use in calves to be processed for veal. Dectomax Injectable for use in swine has a 24-day pre-slaughter withdrawal period. Use of Dectomax or Dectomax-CA1 in dogs may result in fatalities. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.

DISCLOSURE NOTICES

Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to expectations regarding products, product approvals or licenses, products under development and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

ZTS-COR

ZTS-IR

ZTS-FA

¹ APHIS. https://www.aphis.usda.gov/sites/default/files/nws-historical-economic-impact.pdf. Accessed 8/15/25